Study drug for children with low platelets
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new medicine for children with a condition called immune thrombocytopenia (ITP), which causes low blood platelets and easy bruising or bleeding. It may help increase platelet counts when standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 18 years old.
- You have been diagnosed with primary ITP for at least 12 months.
- Your platelet count was below 30 (×10⁹/L) within 48 hours before starting the study.
- You have not had certain ITP treatments in the past 2 weeks (or 4 weeks for some medications).
- You must be able to visit the clinic and follow study procedures.
- If you are of childbearing age, you must agree to use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
This study tests a sequence of two medicines that help raise platelet counts in people with severe ITP. The first is given as an injection, and the second is a pill, and they are given after standard steroid treatment. The goal is to see if this approach can improve platelet levels safely.
Hear when a new Thrombocytopenia, Immune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.